Search Medical Condition
Please enter condition
Please choose location

Nuertingen, Germany Clinical Trials

A listing of Nuertingen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (29) clinical trials

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

The purpose of this study is to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study will also evaluate the safety of enzalutamide plus ADT in mHSPC.

Phase

0.0 miles

Learn More »

Therapeutic Instillation of Mistletoe

This is a randomized, open-label, active-controlled, prospective, multinational Phase III confirmative study with 2 treatment groups and an adaptive design (Bauer and Köhne, 1994). The study is designed to compare the efficacy of treatment with abnobaVISCUM® 900 with Mitomycin C (MMC). Patients with completely resected superficial bladder carcinoma (Stage Ta) ...

Phase

1.39 miles

Learn More »

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

The duration of the study per patient will be approximately 2 years. Each patient will be treated until radiographic disease progression, unacceptable toxicity, or patient's refusal of further study treatment, and each patient will be followed after completion of study treatment until death, study cutoff date, or withdrawal of patient ...

Phase

1.39 miles

Learn More »

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Subjects should continue on the treatment regimen that the subject was receiving in the prior study. Dose changes of any of the prior therapies subjects were receiving on the previous protocol are allowed after medical monitor approval. The day 1 visit for this study should coincide with the last treatment ...

Phase

1.39 miles

Learn More »

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with ...

Phase

1.39 miles

Learn More »

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis in Comparison to Darbepoetin Alfa

This study will consist of three study periods as follows: - Screening Period: from 2 up to 6 weeks - Treatment Period: 104 weeks - Follow-up Period: 4 weeks

Phase

2.6 miles

Learn More »

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. NOTE: Global recruitment is complete but enrollment is ongoing for the China sub-study. The Completion Date for the Primary Outcome Measure is expected in October 2018.

Phase

2.6 miles

Learn More »

Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients

The new interferon-free antiviral regimens for the treatment of chronic hepatitis C (CHC) infections achieve impressive sustained virological response (SVR) rates beyond 90%, with shorter treatment duration and reduced side effects, irrespective of previous treatment history or presence of advanced liver diseases. In Europe, the majority of HCV infections have ...

Phase N/A

2.6 miles

Learn More »

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil ...

Phase

5.05 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

5.29 miles

Learn More »